Imugene shares have hit a fresh all-time high this morning after the Sydney biotech said its HER-Vaxx cancer vaccine had achieved a clinical milestone in a phase 2 gastric cancer trial.

The 36-patient trial met its secondary endpoint of improving progression-free survival, Imugene said. It didn’t say if the trial hit its primary endpoint of improving overall survival.

“I am delighted to report that we have achieved this significant milestone for patients with advanced gastric cancer,” said Imugene managing director and chief executive Leslie Chong.

Data from the study will be analysed with the final readout expected within months, Imugene said.

“I look forward to updating the market as the data is analysed,” Chong said.


The patients, recruited from Eastern Europe and India, were treated with either HER-Vaxx plus standard chemotherapy or chemotherapy alone.

The HER-Vaxx vaccine is an immunotherapy designed to stimulate an antibody response against cancer cells, namely a target known as HER-2/neu.

At 11.24am, Imugene shares were up 6.8 per cent to 19.75c, even as the overall market was down 1.3 per cent, with every sector in the red.

IMU shares have doubled since the start of March and tripled since early November as the $884 million company makes progress on its cancer vaccine.